IQVIA LABORATORIES

Alamar NULISA™ Panels — Exceptional Multiplexing Without Compromising Sensitivity

IQVIA Laboratories Protein Biomarkers is an Alamar-certified service provider, delivering reliable, scalable testing using the NULISAseq platform and ARGO system. NULISA delivers exceptional multiplexing without compromising sensitivity, making it an ideal platform for low abundance biomarkers common in neurodegenerative conditions and early stages of inflammation-mediated conditions.



NULISA performance characteristics*

- Ultra-high sensitivity to detect low-abundance proteins — attomolar levels (fg/mL) — which can be critical mechanism-of-action studies
- Scalable multiplexing analyzes hundreds of biomarkers from a single 25 µL sample input without loss of sensitivity, enabling comprehensive biomarker profiling
- Coefficient of variation (CV) <10%, demonstrating exceptional reproducibility across runs and plates
- ~12 logs dynamic range — appropriate for measuring both low-abundance biomarkers and high-abundance biomarkers in the same panel
- Reliable, reproducible results for clinical and translational research.

*performance characteristics determined by Alamar

IQVIA Laboratories is an Alamar-certified service provider

In becoming Alamar-certified, our Protein Biomarkers lab demonstrated:

TECHNICAL EXPERTISE

Proven expertise in high-sensitivity detection methods and experience in sample management.

OPERATIONAL STANDARDS

Adherence to Good Laboratory Practices (GLP) and other relevant industry standards, and demonstrated robust quality control procedures, including validation of assay results.

FACILITY REQUIREMENTS

Appropriate conditions to perform NULISA assays.

As the Protein Biomarker Center of Excellence within IQVIA Laboratories, our lab team delivers:

- Decades of expertise in biomarker development and validation
- SOP workflows for consistent, high-quality data
- Expert guidance from assay selection to interpretation
- Documented quality processes, including IQ/OQ/PQ and concordance testing
- Custom assay development capabilities on various platforms
- Ability to test on multiple platforms

Available NULISA panels include:

NULISAseq Inflammation Panel AQ

- Detects biomarkers across 250 targets with quantitative measurements for 150 inflammatory biomarkers including cytokines, chemokines and growth factors
- Includes biomarkers with clinical utility in developing biosignatures for early detection, disease progression and measuring therapeutic response
- Enables deeper understanding of inflammatory processes relevant to therapeutic efficacy and safety across conditions such as lupus, rheumatoid arthritis, vasculitis and inflammatory bowel disease
- Supports a range of applications, including pharmacodynamic studies, cohort comparisons (diseased vs. healthy populations), and longitudinal or population health studies to track changes in key proteins over time

NULISAseq Inflammation Panel 250

- Broad coverage to analyze 250 inflammatory biomarkers, including cytokines, chemokines and inflammatory mediators
- Includes low-abundance biomarkers, enabling detection of biomarkers that other technologies may miss
- Gain insights into early disease biosignatures in inflammatory conditions such as autoimmune diseases, neuroinflammatory conditions and immuno-oncology

NULISAseq CNS disease panel 120

- Detects 120 proteins from minimal sample volumes (25 µL)
- Detects analytes with utility in discriminating between neurodegenerative conditions, including amyloid betas, pTaus and synucleins
- Attomolar sensitivity enables detection of low-abundance biomarkers that are not well suited to traditional platforms or technologies
- Ideal for identifying and understanding complex pathways involved in neurodegenerative and neuroinflammatory conditions, such as Alzheimer's, Parkinson's and multiple sclerosis. These biomarkers can be critical in evaluating new therapeutics for neurodegenerative conditions.

CONTACT US
labs.iqvia.com

IQVIA LABORATORIES